New Delhi: Serum Institute of India (SII) and Bharat Biotech have not been granted emergency use authorisation of their coronavirus vaccine because of inadequate safety and efficacy data. According to ...
Hyderabad: Pfizer and the Serum Institute of India (SII) had already sought emergency use approval for their COVID-19 vaccines from the Drug Controller General of India (DCGI). Now, Hyderabad-based Bharat ...
New Delhi: Prime Minister Narendra Modi will visit India’s three pharma majors on Saturday to personally review the development of COVID-19 vaccine and the manufacturing process. “As India enters a ...
Bhubaneswar: India's indigenous COVID-19 vaccine Covaxin reportedly faced an adverse incident during its Phase I trial back in August. The company claims that it reported the incident within 24 hours. ...
New Delhi: With last-stage trials beginning this month, the Indian government-backed COVID-19 vaccine could be launched in February. Since studies so far show that it is safe and effective, it ...
Hyderabad: Bharat Biotech's vaccine Covaxin is expected to be launched in Q2 of 2021 pending approvals from authorities. The phase 3 trials will be started at the earliest across the ...
New Delhi: Covaxin, India's first indigenous COVID-19 vaccine candidate, developed by Bharat Biotech is expected to have at least 60 per cent effectiveness, Hindustan Times (HT) reported. The Drugs Controller ...
New Delhi: The Bharat Biotech developed-vaccine in collaboration with the Indian Council of Medical Research (ICMR) — Covaxin — has got the approval for the third phase of clinical trials. ...
New Delhi: Union Health Minister Harsh Vardhan said that late-stage clinical trials of intranasal COVID-19 vaccines are expected to be pursued by Serum Institute of India and Bharat Biotech once ...
New Delhi: Covaxin, India's first indigenous COVID vaccine, will use adjuvant Alhydroxiquim-II to increase immune response, informed Bharat Biotech on Monday. ViroVax LLC, a Kansas based company, has licensed their ...
Copyright © 2024 Frontier Media
